ArticleJournal of thoracic disease2012
Breast cancer manifested by hematologic disorders.
Article in Journal of thoracic disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Trial
- Knockdown of Nemo‑like kinase promotes metastasis in non‑small‑cell lung cancer.Oncology reports · 2019Article
- MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer.Oncology letters · 2017Article
- PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Optimization of apparent diffusion coefficient measured by diffusion-weighted MRI for diagnosis of breast lesions presenting as mass and non-mass-like enhancement.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer.PloS one · 2013Article
- Foxo3a expression is a prognostic marker in breast cancer.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common type of cancer in women. However, it is very rarely manifested as hematologic disorders. A 35-year-old woman was admitted because of disseminated intravascular coagulation. Examinations revealed the presence of breast cancer in her left breast; therefore, paclitaxel was administered weekly. Although disseminated intravascular coagulation was controlled, pulmonary dysfunction due to lymphangitis carcinomatosa suddenly occurred 10 weeks after treatment. Pulmonary dysfunction was effectively treated with epirubicin and cyclophosphamide. Twenty-three weeks after treatment, the patient developed liver dysfunction accompanied with jaundice due to progressive metastatic lesions in the liver; liver dysfunction improved after the administration of vinorelbine. Subsequently, because of the recurrence of pulmonary dysfunction, rechallenge with epirubicin and cyclophosphamide was performed and was effective; however, this therapy was discontinued because of its adverse effects. She expired of liver failure 33 weeks after the occurrence of disseminated intravascular coagulation. Metastatic tumors in the bone marrow, lung, and liver showed different sensitivities to different anti-cancer agents. We report a case of breast cancer manifested by hematologic disorders which was treated by a sequential chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.